Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma

Trial Profile

A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs TAK 659 (Primary) ; Venetoclax
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 23 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 29 Jan 2018 Planned initiation date changed from 29 Nov 2017 to 15 Feb 2018.
    • 04 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top